2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 216

Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies
Abstract Number: 432

Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry
Abstract Number: 2810

Does Loss-of-function Variants in SAT1 Cause X-linked Pediatric Lupus?
Abstract Number: 1676

Does Pneumocystis Jiroveci Pneumonia (PJP) Prophylaxis Prevent Hospitalizations for Other Infections in Vasculitis Patients?
Abstract Number: 1662

Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss)Really Exist?
Abstract Number: 1551

Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Abstract Number: 2924

Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?
Abstract Number: 289

Doppler in Entheses: A Potential Useful Outcome in Active Spondyloarthritis and Psoriatic Arthritis
Abstract Number: 1153

Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population
Abstract Number: 1687

Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis
Abstract Number: 586

Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial
Abstract Number: 752

Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Abstract Number: 2856

Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Abstract Number: 1555

Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry
Abstract Number: 1548

Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].